Literature DB >> 20851591

Contrasting pressure-support ventilation and helium-oxygen during exercise in severe COPD.

Omar Hussain1, Eileen G Collins, Nalan Adiguzel, W Edwin Langbein, Martin J Tobin, Franco Laghi.   

Abstract

Helium-oxygen mixtures and pressure-support ventilation have been used to unload the respiratory muscles and increase exercise tolerance in COPD. Considering the different characteristics of these techniques, we hypothesized that helium-oxygen would be more effective in reducing exercise-induced dynamic hyperinflation than pressure-support. We also hypothesized that patients would experience greater increases in respiratory rate and minute ventilation with helium-oxygen than with pressure-support. The hypotheses were tested in ten patients with severe COPD (FEV(1) = 28 ± 3% predicted [mean ± SE]) during constant-load cycling (80% maximal workrate) while breathing 30% oxygen-alone, helium-oxygen, and pressure-support in randomized order. As hypothesized, helium-oxygen had greater impact on dynamic hyperinflation than did pressure-support (end-exercise; p = 0.03). For the most part of exercise, respiratory rate and minute ventilation were greater with helium-oxygen than with pressure-support (p ≤ 0.008). During the initial phases of exercise, helium-oxygen caused less rib-cage muscle recruitment than did pressure-support (p < 0.03), and after the start of exercise it caused greater reduction in inspiratory reserve volume (p ≤ 0.02). Despite these different responses, helium-oxygen and pressure-support caused similar increases in exercise duration (oxygen-alone: 6.9 ± 0.8 min; helium-oxygen: 10.7 ± 1.4 min; pressure-support: 11.2 ± 1.6 min; p = 0.003) and similar decreases in inspiratory effort (esophageal pressure-time product), respiratory drive, pulmonary resistance, dyspnea and leg effort (p < 0.03). In conclusion, helium-oxygen reduced exercise-induced dynamic hyperinflation by improving the relationship between hyperinflation and minute ventilation. In contrast, pressure-support reduced hyperinflation solely as a result of lowering ventilation. Helium-oxygen was more effective in reducing exercise-induced dynamic hyperinflation in severe COPD, and was associated with greater increases in respiratory rate and minute ventilation than pressure-support.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20851591     DOI: 10.1016/j.rmed.2010.08.008

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  5 in total

Review 1.  Pathogenesis of hyperinflation in chronic obstructive pulmonary disease.

Authors:  Philippe Gagnon; Jordan A Guenette; Daniel Langer; Louis Laviolette; Vincent Mainguy; François Maltais; Fernanda Ribeiro; Didier Saey
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-02-15

Review 2.  Noninvasive ventilation with helium-oxygen mixture in hypercapnic COPD exacerbation: aggregate meta-analysis of randomized controlled trials.

Authors:  Fekri Abroug; Lamia Ouanes-Besbes; Zeineb Hammouda; Saoussen Benabidallah; Fahmi Dachraoui; Islem Ouanes; Philippe Jolliet
Journal:  Ann Intensive Care       Date:  2017-06-06       Impact factor: 6.925

3.  Inhibition of central activation of the diaphragm: a mechanism of weaning failure.

Authors:  Franco Laghi; Hameeda Shaikh; Stephen W Littleton; Daniel Morales; Amal Jubran; Martin J Tobin
Journal:  J Appl Physiol (1985)       Date:  2020-07-16

4.  Quadriceps Endurance Increases Following Cycling Exercise With Non-Invasive Ventilation In Moderate-To-Severe COPD Patients. A Non-Randomized Controlled Study.

Authors:  Pierre Labeix; Mathieu Berger; Isabelle Court Fortune; Léonard Feasson; Samuel Verges; Frédéric Costes
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-11-05

5.  Bench experiments comparing simulated inspiratory effort when breathing helium-oxygen mixtures to that during positive pressure support with air.

Authors:  Andrew R Martin; Ira M Katz; Katharina Jenöfi; Georges Caillibotte; Laurent Brochard; Joëlle Texereau
Journal:  BMC Pulm Med       Date:  2012-10-03       Impact factor: 3.317

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.